Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

Vaccine. 1996 Jun;14(9):930-8. doi: 10.1016/0264-410x(95)00258-3.


The immunotherapy of cancer requires the definition of a suitable target for and the induction of a CD8+ cytotoxic lymphocyte reaction. In breast cancer, particularly mucins (MUC1) of the variable number of tandem repeat sequence may be a suitable target, but there has been a problem in inducing a cytotoxic response. MUC1 peptides, conjugated to carriers (keyhole-limpet hemocyanin or diphtheria toxoid) induce a humoral response and give poor tumor protection in mice and there is little cellular immunity. However, when MUC1 fusion protein is conjugated to mannan under oxidizing conditions, a cellular immune response is induced, with significant tumor protection, cytotoxic T lymphocytes and little antibody. The procedure may also be useful for other antigens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Female
  • Hypersensitivity, Delayed / immunology
  • Immunity, Cellular / immunology*
  • Mannans / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Molecular Sequence Data
  • Mucin-1 / immunology*
  • Neoplasms, Experimental / prevention & control
  • Recombinant Fusion Proteins / immunology*
  • T-Lymphocytes, Cytotoxic / immunology


  • Mannans
  • Mucin-1
  • Recombinant Fusion Proteins